Selective modulation of ␣7 nicotinic acetylcholine receptors (nAChRs) is thought to regulate processes impaired in schizophrenia, Alzheimer's disease, and other dementias. One approach to target ␣7 nAChRs is by positive allosteric modulation. Structurally diverse compounds, including PNU-120596, 4-naphthalene-1-yl-3a,4,5,9b-tetrahydro-3-H-cyclopenta[c]quinoline-8-sulfonic acid amide (TQS), and 5-hydroxyindole (5-HI) have been identified as positive allosteric modulators (PAMs), but their receptor interactions and pharmacological profiles remain to be fully elucidated. In this study, we investigated interactions of these compounds at human ␣7 nAChRs, expressed in Xenopus laevis oocytes, along with genistein, a tyrosine kinase inhibitor. Genistein was found to function as a PAM. Two types of PAM profiles were observed. 5-HI and genistein predominantly affected the apparent peak current (type I) whereas PNU-120596 and TQS increased the apparent peak current and evoked a distinct weakly decaying current (type II). Concentration-
responses to agonists [ACh, methylidene]-5,6-dihydro-4H-pyridin-2-yl]pyridine dihydrochloride , and N- [(3R)-1-azabicyclo[2.2.2] oct-3-yl]-4-chlorobenzamide hydrochloride (PNU-282987)] were potentiated by both types, although type II PAMs had greater effects. When applied after ␣7 nAChRs were desensitized, type II, but not type I, PAMs could reactivate ␣7 currents. Both types of PAMs also increased the ACh-evoked ␣7 window currents, with type II PAMs generally showing larger potentiation. None of the PAMs tested increased nicotineevoked Ca 2ϩ transients in human embryonic kidney 293 cells expressing human ␣4␤2 or ␣3␤4 nAChRs, although some inhibition was noted for 5-HI, genistein, and TQS. In summary, our studies reveal two distinct ␣7 PAM profiles, which could offer unique opportunities for modulating ␣7 nAChRs in vivo and in the development of novel therapeutics for central nervous system indications.
Nicotinic acetylcholine receptors (nAChRs) belong to the pentameric superfamily of ligand-gated ion channels that includes 5HT 3 , GABA A , and glycine receptors. Twelve neuronal nicotinic subunits have been identified thus far (␣2-␣10; ␤2-␤4) of which nine subunits, ␣2-␣7 and ␤2-␤4, predominate in the mammalian brain (Paterson and Nordberg, 2000) . Multiple functionally distinct nAChR complexes can be assembled either as homomeric functional pentamers, such as ␣7 nAChRs (Couturier et al., 1990) , or as heteropentamers with at least two different subunits, such as ␣4␤2 nAChRs (Gotti et al., 2006) .
The role of ␣7 nAChRs in the CNS has received much attention since their discovery (Couturier et al., 1990) . These subunits, when expressed in heterologous expression systems, activate and desensitize rapidly and, furthermore, exhibit relatively higher calcium permeability compared with other nAChR combinations (Dajas-Bailador and Wonnacott, 2004) . In the brain, the ␣7 subunit is distributed at high levels, including in regions involved in learning and memory, hippocampus and cerebral cortex (Rubboli et al., 1994; Wevers et al., 1994; Breese et al., 1997) . At the cellular level, activation of ␣7 nAChRs is thought to regulate interneuron excitability (Frazier et al., 1998) , modulate the release of excitatory and inhibitory neurotransmitters (Alkondon et al., 2000) , and contribute to neuroprotective effects in experimental in vitro models of cellular damage (Levin and Rezvani, 2002) . Antisense (Curzon et al., 2006) and more recent gene knock-out studies (Wehner et al., 2004; Keller et al., 2005) have demonstrated that ␣7 nAChRs could play important roles in certain cognitive and attentive tasks. For example, ␣7 nAChR genetic knockout mice have shown impaired performance in ethanol-induced contextual fear conditioning (Wehner et al., 2004) and showed further deterioration in hippocampus-selective associative learning and memory when crossed with Tg2576 animals (Dineley et al., 2005) . Selective ␣7 nAChR agonists such as PNU-282987 (Hajós et al., 2005) , PHA-543613 (Wishka et al., 2006) , and AR-R17779 (Felix and Levin, 1997; Van Kampen et al., 2004) improve performance in sensory gating, novel object recognition, social recognition, water maze performance, or inhibitory avoidance models of cognitive function. Given these roles, targeting ␣7 nAChRs has been considered as a viable strategy for a variety of diseases involving cognitive deficits and neurodegeneration (for review, see Levin and Rezvani, 2002; Gotti et al., 2006 ).
An alternate approach to enhance ␣7 nAChR function is by augmenting effects of the neurotransmitter ACh via positive allosteric modulation that could reinforce the endogenous cholinergic neurotransmission without directly activating ␣7 nAChRs. Indeed, such positive allosteric modulator (PAM) approach to enhance channel activity has been proven clinically successful for GABA A receptors (Hevers and Luddens, 1998) . The preclinical validation of ␣7 nAChR PAMs will require selective compounds yet to be identified because many of the compounds identified so far are weak, nonselective or incompletely characterized pharmacologically. Various molecules have been reported to positively modulate ␣7 nAChR, including PNU-120596 , 5-hydroxyindole (5-HI) (Zwart et al., 2002) , ivermectin (Krause et al., 1998) , galantamine (Samochocki et al., 2003) , bovine serum albumin (Conroy et al., 2003) , SLURP-1 (Chimienti et al., 2003) , an acetylcholinesterase derived peptide (Zbarsky et al., 2004) , (2-amino-5-keto)thiazole compounds (Broad et al., 2006) , and compound 6 (Ng et al., 2007) . Among these compounds, PNU-120596 and compound 6 improved auditory gating and other cognitive deficits Ng et al., 2007) , supporting the concept that ␣7 nAChR PAMs may be effective in vivo. Genistein, a nonselective kinase inhibitor (Akiyama et al., 1987) has been shown to increase ␣7 responses (Charpantier et al., 2005; Cho et al., 2005) . Although there was evidence that effects of genistein could be mediated through kinase inhibition, direct allosteric modulatory effects on ␣7 nAChR may be involved, and detailed studies aimed at identifying direct effects of genistein on ␣7 nAChR have yet to be carried out.
This study describes the pharmacological profiles of structurally diverse PAMs: 5-HI, PNU-120596, and TQS. In addition, evidence is presented that genistein also functions as an ␣7 nAChR PAM. The effects of these compounds were determined on recombinant ␣7 current evoked by diverse ␣7 agonists [ACh, GTS-21 (de Fiebre et al., 1995) , and PNU-282987 (Bodnar et al., 2005) ] as well as on ␣4␤2 and ␣3␤4 nAChRs to investigate their selectivity. Our results demonstrate the existence of at least two types of ␣7 nAChR PAMs based upon differential effects on current responses, reactivation of desensitized ␣7 nAChRs, augmentation of ACh window current, and agonist concentration-response characteristics. This study provides an insight into the understanding of PAM actions relevant to the design of novel compounds with potential therapeutic utility in diseases such as: Alzheimer's disease, schizophrenia, and attention deficit hyperactivity disorder, where ␣7 nAChRs are thought to play important roles.
Materials and Methods
Materials. Oocytes were obtained from adult female Xenopus laevis frogs (Blades Biological Ltd., Cowden, Edenbridge, Kent, UK) and cared for in accordance with the Institutional Animal Care and Use Committee guidelines. Genistein, 5-hydroxindole, herbimycin A, ACh, nicotine, choline, MLA, and BAPTA-AM were obtained from Sigma (St. Louis, MO). GTS-21 and staurosporine were purchased from Tocris (London, UK). PP2 and SU6656 were obtained from Biaffin GmbH and Co KG (Kassel, Germany). PNU-120596, TQS, and PNU-282987 were synthesized in-house. All other chemicals and reagents were obtained from Sigma or Fisher Scientific (Essex, UK).
Two-Electrode Voltage-Clamp on X. laevis Oocytes. X. laevis oocytes were prepared for electrophysiological experiments as described previously (Briggs et al., 1995; Briggs and McKenna, 1998) . In brief, three to four lobes from ovaries of female adult X. laevis frogs were removed and defolliculated after treatment with collagenase type 1A (2 mg/ml; Sigma) prepared in low-Ca 2ϩ Barth's solution [90 mM NaCl, 1.0 mM KCl, 0.66 mM NaNO 3 , 2.4 mM NaHCO 3 , 10 mM HEPES, 2.5 mM sodium pyruvate, 0.82 mM MgCl 2 , and 0.5% (v/v) penicillin-streptomycin solution, pH ϭ 7.55 (Sigma)] for 1.5 to 2 h at ϳ18°C under constant agitation to obtain isolated oocytes. The oocytes were injected with ϳ4 to 6 ng of human ␣7 nAChR cRNA, kept at 18°C in a humidified incubator in modified Barth's solution [90 mM NaCl, 1.0 mM KCl, 0.66 mM NaNO 3 , 2.4 mM NaHCO 3 , 10 mM HEPES, 2.5 mM sodium pyruvate, 0.74 mM CaCl 2 , 0.82 mM MgCl 2 , 0.5% (v/v) penicillin-streptomycin solution, pH 7.55] and used 2 to 7 days after injection. Responses were measured by two-electrode voltage clamp using parallel oocyte electrophysiology test station (Abbott, Abbott Park, IL) (Trumbull et al., 2003) . During recordings, the oocytes were bathed in Ba 2ϩ -OR2 solution (90 mM NaCl, 2.5 mM KCl, 2.5 mM BaCl 2 , 1.0 mM MgCl 2 , 5.0 mM HEPES, and 0.0005 mM atropine, pH 7.4) to prevent activation of Ca 2ϩ -dependent currents and held at Ϫ60 mV at room temperature (ϳ20°C). Modulators were given for ϳ60 s before agonist application. Agonists were applied for 1 s at 6 ml/s with or without modulators to the recording chambers. The buffer flow to the chamber, however, did not resume until at least 3 s had passed. The parallel oocyte electrophysiology test station system, similar to any other electrophysiological setup using X. laevis oocytes, cannot apply ␣7 agonists fast enough to cause rapid and complete activation of ␣7 channels without desensitization; hence, the measured maximum peak current responses underestimate the maximum achievable current mediated by ␣7 nAChRs. For this reason, we use the term apparent peak current to describe the maximum observed peak current amplitude response. In inhibition experiments, which were carried out as part of the window current analysis, a three-step protocol was used. In the first addition, 1 mM ACh without PAM was applied to obtain a control response. In the second addition, different concentrations of ACh were given in the presence of 3 M PNU-120596, 5 M TQS, 50 M genistein, 1 mM 5-HI, or no PAM (buffer control) for 10 min. After this preincubation, 1 mM ACh in the continual presence or absence of PAM was applied for at least 3 s. This protocol allowed for normalization of the concentration-inhibition curves to 1 mM ACh without PAM. The agonist responses obtained in the presence or absence of PAM were also normalized to 1 mM ACh without PAM ensuring that the same control condition was used in comparing the window current effects. In current-voltage experiments aimed at identifying reversal potentials for initial and secondary components, ␣7 currents were evoked by 100 M ACh in the presence of 1 M TQS while changing the holding potential from Ϫ140 to ϩ80 mV in steps of 20 mV and normalized to the respective initial and secondary current responses measured at Ϫ100 mV taken as Ϫ1.0 for each cell.
Calcium Imaging. Functional activities were assessed in human embryonic kidney 293 cell lines expressing human ␣4␤2 or ␣3␤4 subunits by measuring intracellular calcium changes using a fluorometric imaging plate reader (FLIPR; Molecular Devices, Sunnyvale, CA). Cells were plated at densities of 25 to 60 ϫ 10 3 cells/well in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum in 96-well clear-bottomed, black-walled plates precoated with poly(D-lysine) (75 l/well of 0.01 g/l solution Ն30 min) and allowed to incubate for 24 to 48 h at 37°C in 5% CO 2 in a humidified environment. After aspirating the media, cells were incubated for ϳ45 to 60 min with Fluo-4 AM calcium indicator dye in the dark at room temperature (Invitrogen, Carlsbad, CA) dissolved in N-methyl-D-glucamine (NMDG)/Ringer buffer (140 mM NMDG, 5 mM KCl, 1 mM MgCl 2 , 10 mM HEPES, and 10 mM CaCl 2 , pH 7.4). After dye loading, cells were gently washed with the same buffer removing extracellular dye, leaving ϳ100 l/well after the final wash. Cells were placed in the FLIPR chamber, where 50 l of 3ϫ stock concentration of test modulators or buffer prepared in the same NMDG/Ringer buffer were added to the wells in the first addition for 5 min. In the second addition, also for 5 min, 50 l of 4ϫ stock concentrations of nicotine (3-10 M) or buffer were added.
Data Analysis. In two-electrode voltage-clamp studies, responses were quantified by measuring apparent peak current amplitude. Apparent peak current responses were expressed as percentage response to 100 M ACh when assessing PAM responses or to 1 mM ACh when determining agonist concentration responses. In inhibition experiments, the concentration-responses to preapplied ACh concentrations in the presence or absence of PAM were plotted against the observed effects on 1 mM ACh without PAM as explained above. In calcium imaging studies, raw fluorescence data were corrected by subtracting fluorescence values from wells with buffer only added. Peak fluorescent responses were determined using FLIPR software and expressed as -fold increases over the submaximum nicotine response (3-10 M, corresponding to EC 30 to EC 50 ); 1-fold indicates no change in the response. Data were analyzed and fitted using Prism (GraphPad Software, San Diego, CA 
Results
Modulation of ␣7 nAChRs by PNU-120596, TQS, and 5-HI. First, the effects of representative compounds from structurally diverse chemotypes, including 5-HI (Zwart et al., 2002) , PNU-120596 , and TQS (Becker et al., 2006) were assessed on ␣7 function as agonists and then as PAMs (see Fig. 1 for structures). None of these compounds alone induced activation of ␣7 currents up to the maximum concentrations tested (30 M except for 5-HI, which was tested up to 10 mM) indicating that they are not ␣7 agonists. Under similar conditions, ACh and ␣7 selective agonists such as PNU-282987 were effective in evoking currents (see Modulation of Agonist Concentration-Responses by PAMs). When 5-HI, PNU-120596, and TQS were added to the cells during preincubation and then ␣7 currents were obtained by submaximal concentration of ACh (100 M), concentration-dependent potentiation of current responses was obtained. As shown in Figs. 2 and 3, the rank order of potency, based on apparent peak current amplitude analysis, was PNU-120596 (pEC 50 ϭ 5.8 Ϯ 0.09) Ͼ TQS (pEC 50 ϭ 5.5 Ϯ 0.07) Ͼ 5-HI (pEC 50 ϭ 3.2 Ϯ 0.06). A similar rank order of potency was obtained when total current charge (integral or area under the current response) was analyzed.
PAMs had qualitatively different effects on ACh responses, as exemplified by the traces depicted in Fig. 2 , and could be classified into two types. PNU-120596 and TQS dramatically increased the apparent peak current response and seemed to reduce the current decay rate (designated as type II). At highest concentrations tested, these compounds in the presence of ACh evoked a nondecaying or weakly decaying current during the recording interval (usually 3 s). Typically, at lower concentrations of PNU-120596 (e.g., 1 M; Fig. 2a , trace B) and TQS (e.g., 1 M; Fig. 2b , trace B), the effects on the amplitude were minimal and an apparent secondary component with amplitude similar to that of the initial apparent peak was identifiable. The onset of this secondary component was clearly distinct from that of the initial component. With increasing concentrations of these PAMs, the apparent peak and secondary components overlapped, producing an apparent single current profile with relatively rapid onset and very weak current decay. During washout, when both agonist and PAM were removed, it typically took 50 to 100 s for TQS (Ն10 M) and longer than 200 to 250 sec for PNU-120596 (Ն10 M) for the holding current to return to pretreatment levels, suggesting relatively prolonged effects.
In contrast, 5-HI (and genistein see below) predominantly increased ␣7 nAChR apparent peak amplitude response without robustly affecting current decay rate (designated as type I). Although the decay rate could have been slightly altered, especially at the highest concentrations tested (Fig.  2c , traces C and D); the effects, however, were modest. Furthermore, unlike PNU-120595 and TQS, there was no secondary component identifiable with onset separate from that of the initial apparent peak component. This suggests that the mechanism by which 5-HI allosterically potentiates ␣7 nAChR response is distinct from that mediated by PNU-120596 and TQS. To further characterize the nature of the ACh-evoked secondary component, current-voltage experiments were carried out in which the holding potential was varied from Ϫ140 up to ϩ80 mV, and ACh evoked ␣7 currents measured in the presence of 1 M TQS (see Fig. 4 ). At this concentration of TQS, both initial and secondary components are easily separable. As shown, both initial and secondary current components reversed at ϳ0 mV consistent with their being mediated directly by ␣7 nAChR.
Mechanism of ␣7 nAChR Modulation by Genistein. Genistein is a nonspecific kinase inhibitor (Akiyama et al., 1987) that also increases ␣7 nAChR current response. This effect has been attributed to inhibition of Src kinase, although a direct mechanism involving positive allosteric modulation may be involved (Charpantier et al., 2005; Cho et al., 2005) . To examine whether effects of genistein are due to positive allosteric modulation, three types of experiments were conducted: 1) pre-and coapplication of genistein and ACh to test onset of effects; 2) comparison with other kinase inhibitors; and 3) interaction with 5-HI, another type I PAM.
When added directly, genistein did not activate ␣7 nAChR current up to the maximum tested concentration of 300 M (n ϭ 10). In the continued preincubation with genistein, the apparent peak current ␣7 response was potentiated in a concentration-dependent manner with a pEC 50 value of 4.6 Ϯ 0.1 and maximum potentiation of ϳ 2.6-fold (Figs. 2d and 3) . When preincubation was eliminated and genistein was simply coapplied with ACh, to limit time for potential kinasemediated effects to develop, genistein was still effective in potentiating the ␣7 nAChR response. The degree of potentiation was ϳ2.2-fold without preincubation (Fig. 5a ) compared with ϳ2.6-fold with preincubation ( Fig. 3) , hence ϳ15% less. We also examined the effect of 5-HI under preapplication and coapplication conditions with ACh and determined that this compound exhibited ϳ35% lesser potentiation when coapplied. The -fold increases were ϳ 5.4 (Fig. 3 ) and 3.5 (Fig. 5a ) for pre-and coapplication conditions, respectively.
Staurosporine and herbimycin A, two nonspecific kinase inhibitors (Yanagihara et al., 1991; Zakar et al., 1999) , were also tested to determine their effects on ␣7 currents. Oocytes were exposed to these two inhibitors for 5-to 10-or 60-min preincubation followed by ACh application. At both time points, staurosporine (up to 30 nM) and herbimycin A (up to 10 M) failed to increase or inhibit the ␣7 currents evoked by ACh (n Ն2) (see Fig. 5c ). When genistein was coapplied together with ACh after short-or long-term exposure to either staurosporine (30 nM) or herbimycin A (10 M), the maximum potentiation of the current was similar to that of genistein alone (see Fig. 5b for example) . This observation supports a direct allosteric effect of genistein because this compound was still able to increase ␣7 currents, even though intracellular kinases were inhibited by the treatment with staurosporine or herbimycin A. In addition, we studied the effects of PP2 and SU6656, two Src tyrosine kinase inhibitors that increased ␣7 currents in one study (Charpantier et al., 2005) but not in another (Cho et al., 2005) . In this study, PP2 and SU6656, similarly to herbimycin A and staurosporine, had no effect on ␣7 nAChRs (see Fig. 5c ). These experiments also support a direct allosteric effect of genistein. We rationalized that if genistein effects on ␣7 currents were due primarily to inhibition of protein kinases, then staurospor- ine, herbimycin A, PP2, or SU6656 should mimic the effects of genistein, and they should abolish or attenuate the increased current responses to genistein. As shown, the data support the contrary hypothesis that genistein effects are primarily mediated by a direct allosteric effect on the ␣7 nAChR.
Finally, the interaction of genistein and 5-HI, both type I PAMs, was evaluated by exposing oocytes to a nearly fully efficacious concentration of either 5-HI or genistein followed by determination of the concentration-dependent effects of the other modulator. As shown in Fig. 5d , the net modulatory effect of 5-HI was attenuated by pretreatment with 50 M genistein. Likewise, the effect of genistein was occluded by pre-exposure with 3 mM 5-HI. This lack of additivity is consistent with the hypothesis that the 5-HI and genistein act through a similar mechanism, but the results do not exclude the possibility that the nonadditivity was due to a ceiling effect such that either compound alone could exert the maximum possible effect.
Differential Reactivation of Desensitized ␣7 nAChR by PAMs. To investigate the effects of modulators on desensitized ␣7 nAChRs, oocytes were first exposed to 100 M ACh for at least 60 s (and up to 5 min) to desensitize the channels. Subsequently, in the continued presence of ACh, modulators were applied (for a 4-min interval) followed by washout of the modulator and ACh. As exemplified by Fig. 6 , the addition of either 100 M genistein (n ϭ 4) or 3 mM 5-HI (n ϭ 4) caused no change in current responses. However, when 3 M PNU-120596 (n ϭ 4) or 5 M TQS (n ϭ 4) was added, there was an increase in the ␣7 current. This indicates that modulators that affect both apparent peak current response and evoke the secondary component are able to re-activate currents when ␣7 channels are desensitized. On the other hand, 5-HI and genistein, neither of which evokes the secondary component, do not exhibit this property.
Experiments were also done in presence of MLA, an ␣7 antagonist, or BAPTA-AM, a membrane permeable intracellular Ca 2ϩ chelator. MLA at 100 nM completely abolished the ability of 3 M PNU-120596 or 5 M TQS (n Ն 2) to reactivate desensitized ␣7 nAChR in the presence of ACh (data not shown). In BAPTA-AM experiments, oocytes were incubated with 100 M BAPTA-AM for at least 3 h, allowing for sufficient chelation of cytosolic Ca 2ϩ . Both 3 M PNU-120596 and 5 M TQS (n Ն 2) were able to reactivate ␣7 channels without obvious differences in responses, whether treated with BAPTA-AM or not (data not shown The interval between the traces was at least 3 min. b, the mean current-voltage relationship for the ACh evoked initial and secondary components (n ϭ 2). The responses were normalized to Ϫ100 mV for each cell (taken as the normalized current of Ϫ1.0 at this voltage) and illustrate that both initial and secondary components reverse at ϳ0 mV consistent with both being mediated directly by ␣7 nAChR.
Fig. 5.
Potentiation of ␣7 nAChR currents by genistein involves direct effects. a, the concentration-responses to 5-HI and genistein added as coapplication without any preincubation. The respective mean pEC 50 and maximum efficacy values are 2.8 Ϯ 0.1 and 350 Ϯ 7% for 5-HI and 4.4 Ϯ 0.1 and 227 Ϯ 10% for genistein; each data point is n ϭ 4 to 6. b, representative ␣7 current traces obtained before and after prolonged treatment with staurosporine for either ACh alone or ACh with genistein treatment. Currents in response to 100 M ACh in traces i and ii are before and after, respectively, 60-min treatment with 30 nM staurosporine. Currents in response to 100 M ACh and 100 M genistein in traces iii and iv are before and after, respectively, 60-min treatment with 30 nM staurosporine. c, the effects of different tyrosine kinase inhibitors on ␣7 nAChR currents after at least 5-min preincubation. Among these inhibitors, only genistein potentiated the current evoked by 100 M ACh. Each data point is n Ն 4, ‫ء‬ indicates p Ͻ 0.05. d, the concentration responses to potentiate ␣7 currents by 5-HI in the presence of nearly maximal concentration of genistein and by genistein in the presence of nearly maximal concentration of 5-HI. Each data point is n ϭ 3.
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EC 70-80 in modulator concentration-response experiments: 3 M PNU-120596, 5 M TQS, 50 M genistein, and 1 mM 5-HI) followed by determination of agonist concentrationresponses in the continued presence of the modulator. In particular, we aimed to compare the effects of the different modulators on concentration responses to full agonists, ACh and PNU-282987 (Bodnar et al., 2005) , and a partial ␣7 agonist, GTS-21 (de Fiebre et al., 1995) . As summarized in Table 1 and Figs. 7 and 8, the modulators affected the concentration-responses to all three agonists by shifting the potencies and increasing the maximum responses. The highest enhancement in efficacy was observed with GTS-21. In the absence of any PAM, GTS-21 behaved as a weak partial agonist (pEC 50 Ͻ 3, max ϭ 26.5% at 300 M). However, in the presence of any of the four modulators, GTS-21 became more efficacious, with maximum responses in the range of ϳ70 to 170%. Table 1 also indicates that 5-HI and genistein affected the agonist potencies to a lesser extent than did PNU-120596 and TQS, differences ranging from 0.2 to 0.6-log units. For example, for ACh (pEC 50 of 3.9 without any modulator), 5-HI and genistein shifted the potency by 0.3 to 0.4 log units, whereas PNU-120596 and TQS shifted by 0.8 to 0.9 log units. This suggests that modulators affecting both apparent peak current and secondary component generation are more likely to shift the concentration-response profile to ␣7 agonists to a greater extent than would modulators altering only the apparent peak current response.
Effect of PAMs on ACh Window Current. It is well established that ␣7 nAChRs are activated and desensitized by agonists. In fact, the constants for half-maximum inhibition or desensitization (pIC 50 ) are 1 or 2 orders of magnitude higher that those for activation (pEC 50 ), resulting in a very minimal window current (i.e., the overlap between the activation and inactivation) (Briggs and McKenna, 1998) . The effects of modulators on the ACh window current were therefore examined. The activation curves to ACh, discussed above and summarized in Fig. 9 and Table 1 , showed differential abilities of PAMs to shift the potencies and efficacies. In contrast, the PAMs did not seem to have any significant effect on the ACh concentration-inhibition curves (see Fig. 9 ). As shown, the pIC 50 for the inactivation curve of ACh was 5.1 Ϯ 0.05 (n ϭ 4). In the presence of TQS, PNU-120596, genistein, and 5-HI, the pIC 50 values were 4.9 Ϯ 0.03 (n ϭ 3), 4.8 Ϯ 0.04 (n ϭ 4), 4.7 Ϯ 0.1 (n ϭ 3), and 4.8 Ϯ 0.04 (n ϭ 3), respectively. As a measure of the window currents, we have calculated the integral of the overlapping area of the inhibition and activation curves for the different modulators tested. For ACh, the normalized ratios in the absence of any modulator and in the presence of genistein, 5-HI, TQS, and PNU-120596 were 1 (control, ACh alone), 6, 7, 12, and 17, respectively. This analysis indicates that PNU-120596 and TQS, both type II PAMs, produced more robust effects on ACh window currents than 5-HI and genistein, both type I PAMs.
Effects of PAMs on ␣4␤2 and ␣3␤4 nAChRs. To investigate the selectivity of modulation, the effects of 5-HI, genistein, TQS, and PNU-120596 were measured in recombinant human embryonic kidney 293 nAChR cell lines expressing either human ␣4␤2 or human ␣3␤4 using submaximum concentrations of nicotine (3-10 M) to evoke Ca 2ϩ transients. Genistein, TQS, or PNU-120596 alone did not affect basal Ca 2ϩ in either of the two cell lines. 5-HI up to 1 mM had no effect. However, at 3 and 10 mM, it alone transiently decreased fluorescence in both cell lines followed by a slow recovery in the signal. Overall, submaximum nicotine evoked Ca 2ϩ signals were not increased by the tested PAMs. PNU-120596 produced only small ϳ0.1-to 0.2-fold decreases in the nicotine-evoked Ca 2ϩ signals in the two cell lines tested (Table 2) . TQS also produced a small maximum reduction of ϳ0.1-fold on ␣3␤4 responses and a decrease of ϳ0.7-fold in ␣4␤2 responses. Likewise, genistein and 5-HI decreased nicotine-evoked signals mediated by the two subunit combinations by ϳ0.4-to 0.8-fold. Hence, modulators at the concentrations showing positive effects on ␣7 function did not potentiate or increase Ca 2ϩ signals mediated by ␣3␤4 and ␣4␤2 nAChRs. However, at comparable or higher concentra- 
Discussion
This study compares and contrasts the properties of four structurally distinct ␣7 nAChR modulators-PNU-120596, TQS, 5-HI, and genistein-and demonstrates important distinctions in their pharmacological profiles. We extend earlier observations made with PNU-120596 and 5-HI (Zwart et al., 2002; Hurst et al., 2005) and provide evidence that genistein effects on ␣7 nAChR are due primarily to a positive allosteric mechanism rather than via inhibition of protein kinases. We also characterize for the first time the properties of TQS as an ␣7 PAM. All four compounds increased currents evoked by ␣7 nAChR agonists. Based on their profiles, two types were recognized. Type I PAMs, exemplified by genistein and 5-HI, predominantly affected the apparent peak current response. Type II PAMs, illustrated by PNU-120596 and TQS, increased the apparent peak current amplitude and strongly evoked the secondary component with onset distinguishable from the initial apparent peak component especially at lower concentrations. Both types exhibit differential properties. Type II modulators were able to reactivate desensitized ␣7 nAChRs, whereas type I did not. The former had also greater effects on the ␣7 activation concentration-response curves.
The ACh inhibition curves for ␣7 currents were affected similarly by type I and II compounds resulting in greater ACh window current effects by PNU-120596 and TQS rather than genistein and 5-HI. None of the four compounds, at concentrations active on ␣7, potentiated ␣4␤2 and ␣3␤4 nAChRs indicating that positive allosteric effects are selective for the ␣7 subtype.
Genistein Is a PAM of ␣7 nAChR. Genistein, a tyrosine kinase inhibitor, has been shown to increase ␣7 currents expressed in X. laevis oocytes, in rat hippocampus brain slice interneurons, and stably expressed in SH-SY5Y neuroblastoma cells (Charpantier et al., 2005; Cho et al., 2005) . We have confirmed this increase of ␣7 currents. However, the mechanism underlying this effect remains controversial. In one study, evidence was provided for genistein causing rapid up-regulation of ␣7 receptors at the cell surface membrane (Cho et al., 2005) . In contrast, another report identified no changes in cell surface labeling on neurons with 125 I-␣-bungarotoxin (Charpantier et al., 2005) . Genistein coapplication with agonist was found to be either effective (Charpantier et al., 2005) or ineffective (Cho et al., 2005) in potentiating ␣7 currents. Effects of genistein have been interpreted to occur via tyrosine dephosphorylation of non-␣7 nAChR protein(s) rather than direct allosteric effect on ␣7 nAChR. Effects of PP2, another tyrosine kinase inhibitor, on ␣7 currents are a At the highest tested concentration, 300 M, the response was 26.5 Ϯ 3.9%. The n values are 3 to 9. -120596 (3 M) . Each data point is n ϭ 3 to 6. Summary of potency and maximum efficacy is given in Table 1 .
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at ASPET Journals on June 22, 2017 molpharm.aspetjournals.org Downloaded from also inconclusive, with no (Cho et al., 2005) or potentiating (Charpantier et al., 2005) effects reported. In our study, genistein produced effects similar to those of 5-HI under similar testing conditions consistent with a direct allosteric modulation of ␣7 nAChR on the basis of several lines of evidence. First, genistein was effective when coapplied with ACh, indicating that pre-exposure to genistein was not required. Second, only genistein among the kinase inhibitors studied (staurosporine, herbimycin A, PP2, or SU6656), examined at concentrations showing effective kinase inhibition (Yanagihara et al., 1991; Hanke et al., 1996; Zakar et al., 1999; Blake et al., 2000) , increased ␣7 currents. Third, the pretreatment with other tyrosine kinases inhibitors did not abolish or attenuate the modulatory effect of genistein. Fourth, the modulatory effect of genistein on ␣7 nAChR was occluded by effective concentrations of 5-HI and vice versa. This indicates that either both compounds bind to the same modulatory binding site or that there are two separate modulatory sites and activation of either is sufficient to allosterically potentiate ␣7 nAChR to a certain level that cannot be surpassed by activation of the other modulatory site. Distinct Profiles of nAChR PAMs: Type I and II. The electrophysiological analysis of the effects of PAMs indicates that there are at least two distinct modulator profiles: type I, exemplified by 5-HI and genistein, and type II, exemplified by PNU-120506 and TQS. The primary difference between these two types is in their ability to evoke the secondary component. At high concentrations of type II PAMs, the initial and secondary components overlap, producing an apparent single complex. In the study by Hurst et al. (2005) , the effects of PNU-120596 were judged to occur by slowing down the current decay rate. In this study, the concentrationresponses to PNU-120596 and TQS show that at lower concentrations, there are two separate identifiable components. An initial component similar in time course to that of ␣7 agonists evoked in the absence of any PAM, and a secondary nondecaying or weakly decaying current component, which activates with a slower onset. With increasing concentrations of PAMs, the time courses overlap.
The concept of distinct PAM profiles has been postulated earlier although no previous study has compared and demonstrated such differences. For example, 5-HI (Zwart et al., 2002) , ivermectin (Krause et al., 1998) , galantamine (Samochocki et al., 2003) , bovine serum albumin (Conroy et al., 2003) , SLURP-1 (Chimienti et al., 2003) , (2-amino-5-keto)thiazole compounds (LY2087101, LY1078733, and LY2087133) (Broad et al., 2006) , and compound 6 (Ng et al., 2007) have been reported as ␣7 PAMs exhibiting profile characteristic of type I PAMs. PNU-120596 has been shown to exhibit a different profile . This compound increased the apparent peak ␣7 current response and robustly affected the time course of current response. At the single-channel level, PNU-120596 increased mean open time, had no effect on ion selectivity, and had relatively little effect on unitary conductance . PNU-120596 also increased ACh-evoked GABAergic synaptic activity recorded in pyramidal cells similar to effects of 5-HI in interneurons in hippocampus slices (Mok and Kew, 2006) . 5-HI also enhanced ACh-stimulated glutamate evoked postsynaptic currents in cerebellar slices (Zwart et al., 2002) illustrating ␣7 PAM effects on synaptic activity. In this study, we showed that PNU-120596 potentiated the ␣7 currents expressed in X. laevis oocytes with an EC 50 value of 1.6 M (or pEC 50 of 5.8) and maximum poteniation of ϳ4.5-fold, and we demonstrate that TQS is also a type II PAM exhibiting potency and efficacy similar to PNU-120596.
Comparison of Pharmacological Properties of Type I and II PAMs. Our study provides further insight into the pharmacological properties of type I and II PAMs. Compounds belonging to both types were effective in shifting the potencies of agonists to the left and in increasing their maximum efficacies, although type II PAMs were generally more effective (see Table 1 ). These changes are comparable with those reported by others for 5-HI (Zwart et al., 2002) and (a) shows representative traces in X. laevis oocytes expressing ␣7 evoked by ACh (1 mM, normalizing control) or in the presence of genistein (50 M) for PNU-282987 (0.1, 1, and 10 M) added as indicated by the horizontal bars. b, c, and d, the concentration responses to ACh, GTS-21, and PNU-282987, respectively, in the presence or absence of genistein (50 M). Each data point is n ϭ 3 to 6. Summary of potency and maximum efficacy is summarized in Table 1 . PNU-120596 . Among the agonists tested, the greatest effect was observed for GTS-21. In the absence of any modulator, this compound was a partial agonist, and in the presence of any one of the four modulators, GTS-21 turned out to be a very efficacious agonist. Analysis of the inhibition concentration-response curves to ACh revealed that both types of modulators affected the inhibition similarly. In this study, very little window current (overlap between inhibition and activation curves) to ACh alone (Fig. 9) was observed, consistent with previous observations (Briggs and McKenna, 1998) . To our knowledge, effects of modulators on window currents have not been evaluated for any ␣7 PAM. Our studies demonstrate that type II PAMs, PNU-120596, and TQS, had in general larger effects on window currents than type I PAMs, genistein, and 5-HI.
In cultured rat hippocampal neurons, PNU-120956 activated desensitized rat ␣7 currents when studied electrophysiologically using whole-cell, patch-clamp recordings . In addition to confirming this observation at human ␣7 currents, we found that PNU-120596 and TQS produced similar effects evoking current reactivation from desensitized ␣7 nAChRs in contrast to genistein and 5-HI that did not. The characteristics of this reactivated current (specifically its onset and weakly decaying nature) are similar to those of the secondary component described above (see Fig. 3 and Distinct Profiles of nAChR PAMs: Types I and II) suggesting that the same "activated" channel state is responsible for both. The mechanisms responsible for the induction of this activated state remain to be identified and require further investigation. Potential explanations could be that ␣7 nAChR modulators stabilize a new "desensitized-open" state, as in the case of the ␣7V274T mutant (Galzi et al., 1992; Briggs et al., 1999) , or promote a shift in the equilibrium from a desensitized state to the "active" open state and stabilizing the receptor in the latter state as suggested for ivermectin (Krause et al., 1998) .
Selectivity of ␣7 PAMs. Targeting PAMs rather than direct agonist could offer a potential advantage in terms of selectivity because PAM binding sites are likely distinct from agonist/competitive antagonist binding sites that show considerable homology among various nAChR and related ligand-gated ion channels of the cys-loop family. Determination of selectivity of PAMs will be important to avoid potential non-␣7 nAChR interactions. For example, ␣3␤4* receptors are thought to be involved in the control of bladder and cardiac function and ␣4␤2* subunits in reinforcing effects of nicotine related to addiction (see review by Dani and Bertrand, 2007) . In this study, we tested the effects of PNU-120596, TQS, genistein, and 5-HI on ␣4␤2 and ␣3␤4 subunits using Ca 2ϩ flux measurements. None of these compounds evoked increases in the signals mediated by ␣4␤2 and ␣3␤4 nAChRs, indicating that they are selective PAMs for ␣7. Our observations are similar to those reported for PNU-120596 (tested only at 1 M) in recordings from X. laevis oocytes expressing h␣4␤2, h␣3␤4, or h␣9␣10 nAChR and for genistein (at 10 M) on ACh evoked currents in X. laevis oocytes expressing ␣4␤2 and ␣3␤4 subunits (Cho et al., 2005) . In this study, significant inhibition of Ca 2ϩ responses mediated by h␣4␤2 or h␣3␤4 subunits were noted for all compounds except PNU-120596 (see Table 2 ) at concentrations similar or slightly higher than those required for modulation of ␣7; the significance of which remains to be clarified. In addition to effects of 5-HI on nAChRs, this compound also positively modulates 5-HT 3 currents endogenously expressed in NCB-20 cells and N1E-115 neuroblastoma cells (van Hooft et al., 1997) , limiting its usefulness as a tool compound.
In summary, this study shows that structurally distinct ␣7 PAMs can be divided into two types based on their effects on ␣7 currents. Type I PAMs-5-HI and genistein-predominantly affected the apparent peak current response, whereas type II PAMs-PNU-120596 and TQS-increased apparent peak current response and strongly evoked a secondary weakly decaying current. In general, type II but not type I PAMs could reactivate desensitized ␣7 currents and had greater effects shifting ␣7 agonist concentration-responses and on ACh window currents. The identification of distinct functional profiles of ␣7 PAMs and the reported demonstration of PAM efficacy in preclinical in vivo models of cognition provide basis for the development of novel therapeutics for CNS indications for which the ␣7 nAChR is considered a viable target. 
